Morphic Holding Inc. is a biopharmaceutical company that focuses on the development of oral integrin therapies for the treatment of chronic inflammatory and autoimmune diseases. The company was founded in 2015 and is headquartered in Waltham, Massachusetts, USA. Morphic Holding's mission is to leverage its expertise in integrin biology to develop innovative therapies that can transform patient outcomes. Morphic Holding Inc. is listed on the Nasdaq Stock Market under the ticker symbol "MORF."
Integrins are a type of cell surface receptors involved in cell adhesion and signaling. Morphic Holding is dedicated to targeting specific integrins to modulate immune responses and address underlying mechanisms of disease. By developing small-molecule drugs that selectively bind to integrins, the company aims to provide effective and convenient oral treatments for patients.
Morphic Holding has made many strategic collaborations with other leading pharmaceutical companies. The company has entered into partnerships with established industry players, such as AbbVie and Janssen, to accelerate the development of its integrin therapies. These collaborations provide access to additional resources, expertise, and potential future milestones and royalties.
Morphic Holding's key product is MORF-057, an oral integrin inhibitor currently in development for the treatment of inflammatory bowel disease (IBD). By targeting a specific integrin, MORF-057 aims to reduce the chronic inflammation associated with conditions like Crohn's disease and ulcerative colitis. The company has completed Phase 1 clinical trials for MORF-057 and is progressing with further clinical development.
Morphic Holding Inc. is dedicated to advancing the field of integrin biology and developing transformative therapies for patients with chronic inflammatory and autoimmune diseases. With its innovative approach and strategic partnerships, the company strives to bring safe and effective oral treatments to market, potentially improving the lives of those suffering from these debilitating conditions.